BIOME9
- Company typePrivate
- Founded2023
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
BIOME9 firmographics
Firmographics- Name
- BIOME9
- Legal name
- BIOME9
- Website
- https://biome9.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
BIOME9 industry classification
Industry- Product category
- Veterinary Diagnostics
- NAICS
- Veterinary Services (54194), Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Dog and Cat Food Manufacturing (311111)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Veterinary Microbiology & Infectious Disease Testing (Culture/PCR/Serology) (HLAMADAC)
- akta.pro secondary industries
- Microbiome & Metagenomics Services (HLAGANAH), Digestive & Gut Health (Probiotics/Prebiotics/Enzymes) (HLAMALAC), Non-Human Microbiome Therapeutics (veterinary/animal microbiome interventions) (HLAAAFAL)
Keywords
Where BIOME9 is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
BIOME9 business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- GutDiscovery® Test Kits: One-time purchase of at-home microbiome test kit with comprehensive gut health report. Available through veterinary professionals. Analysis using Oxford Nanopore long-read sequencing provides species-level resolution and pathogen detection. Results delivered within approximately 14 days.
- BiomeBites® Personalised Supplements: Recurring revenue from personalised daily supplement plans recommended based on GutDiscovery® test results. Plans typically span 6 months, with ongoing retesting recommended every 6 months to monitor progress and adjust recommendations.
- Research Services: B2B services offered to organisations including pilot studies, clinical trials, and condition-specific research. Includes experimental design support, laboratory services (DNA extraction, 16S rRNA V1-V9 sequencing), data analysis, and metadata customisation using BIOME9's proprietary database and AI methodologies.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Single GutDiscovery® Test + Report |
| One time/ perpetual license | Pay-as-you-go | 2 Tests + Reports Bundle |
| One time/ perpetual license | Pay-as-you-go | 3 Tests + Reports Bundle |
| One time/ perpetual license | Pay-as-you-go | 5 Tests + Reports Bundle |
| One time/ perpetual license | Pay-as-you-go | 10 Tests + Reports Bundle |
| One time/ perpetual license | Pay-as-you-go | 15 Tests + Reports Bundle |
| Subscription | Monthly | 6-Month Supplement Plan |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels8 records
BIOME9 product offering
Product offeringCore offering
BIOME9 provides at-home canine gut microbiome testing via its GutDiscovery® kit, using Oxford Nanopore long-read 16S-rRNA V1–V9 sequencing analysed by the InvisibleHealth® AI platform to deliver species-level bacterial identification, pathogen detection, and personalised health reports. Test results drive tailored BiomeBites® daily supplement plans (pre, pro, and postbiotics). The professional GutDiscovery® service is sold exclusively to vets, behaviourists, and nutritionists, while a consumer-grade gut health test is distributed via Pooch & Mutt and research services are offered to academic and commercial organisations.
Product overview
BIOME9 is a precision pet wellness company offering a portfolio of products centered on canine gut microbiome analysis. The core offering is the GutDiscovery® Test + Report—an at-home stool test using Oxford Nanopore long-read 16S-rRNA sequencing to deliver species-level microbiome profiles. Analysis is powered by the proprietary InvisibleHealth® AI platform, which processes millions of data points to generate personalized health insights. Test results feed into BiomeBites®—personalized soft-chew supplements (pre, pro, and postbiotics). BIOME9 also offers professional research services for veterinary and academic partners. In 2025, the company transitioned to a B2B model, with consumer products (Gut Health Test) now sold through partner Pooch & Mutt while BIOME9 focuses on professional veterinary services and advanced analysis.
Differentiator
Problem solved
Functional benefit
Brands
- GutDiscovery®: Dog gut microbiome test kit with health report providing species-level identification and pathogen detection for veterinary professionals.
- InvisibleHealth®
- BiomeBites®
Products and services
- GutDiscovery® Test + Report At-home canine gut microbiome test kit using Oxford Nanopore long-read 16S-rRNA V1–V9 sequencing for species-level bacterial identification and pathogen detection, delivered with a personalised gut health report and supplement plan. Sold exclusively through veterinary professionals, behaviourists, and nutritionists.
- BiomeBites® Personalised Supplements
Quantifiable outcome
- 80% of customers report noticeable improvements in their dog's overall wellbeing within 8 weeks of following recommendations
- +5 more outcomes
Companies that use BIOME9
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles3 records
BIOME9 technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature7 records
BIOME9 partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core, supporting and minor.
- Pooch & MuttcorePooch & Mutt acquired BIOME9 in 2025, integrating its technology into consumer-accessible gut health testing. BIOME9's GutDiscovery® continues as a professional service for vets (species-level, pathogen detection) while Pooch & Mutt offers the consumer version using short-read 16S sequencing. Both use identical supplement formulations and BIOME9's AI-driven scoring standards based on a database of over 1,400 dogs.
- Guide Dogs UKcoreGround-breaking partnership with Guide Dogs UK to explore and optimise the gastrointestinal health of puppies training to become guide dogs. Initial study includes 100 Labrador and golden retriever puppies using BIOME9's GutDiscovery® test technology to improve digestion, skin health, immunity, behavioural markers, and joint health. Guide Dogs UK is the world's largest assistance dog organisation and the only organisation that breeds and trains guide dogs in the UK.
- Oxford NanoporecoreTechnology partnership for long-read 16S-rRNA sequencing. BIOME9 uses Oxford Nanopore's platform which employs full-length 16S gene sequencing (V1-V9 regions) to achieve species-level taxonomic resolution through the EPI2ME catalogue database. This enables precise identification of bacterial species including closely related strains and pathogenic variants.
- Agxio LimitedsupportingTechnology and bioinformatics partnership for AI and machine learning capabilities supporting BIOME9's InvisibleHealth® platform and data analysis methodologies.
- University of CambridgesupportingAcademic partnership providing research expertise and access to scientific talent. BIOME9's laboratory facility is located at Cambridge Science Park, and the company collaborates with Cambridge on microbiome research initiatives.
- DogilepticsupportingCollaboration with Dogileptic, an organisation supporting dogs living with epilepsy, to explore how the gut microbiome might influence epilepsy conditions and their management in canine patients.
- S&P GlobalminorIndustry recognition and endorsement by S&P Global for standards and industry standing in the pet health and biotechnology sectors.
- Veterinary Clinics & Pet Health ProfessionalscoreNetwork of veterinary clinics, animal behaviourists, and pet nutritionists who distribute BIOME9's GutDiscovery® professional test service. These partners use species-level microbiome analysis for clinical diagnostics, nutritional counselling, and behavioural assessments. Pet insurers increasingly cover tests when recommended by veterinary professionals.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
BIOME9 competitors and assessment
Company assessmentDirect peers
- AnimalBiome: AnimalBiome is the most direct US-based peer, offering at-home gut microbiome testing for dogs and cats using 16S rRNA sequencing with personalized diet and supplement recommendations — the same core proposition as BIOME9.
- Pooch & Mutt: UK-based pet wellness brand that acquired BIOME9 in 2025 and now distributes a consumer gut health test powered by BIOME9 technology. Closely aligned business model in pet nutrition and health.
Emerging players
- Embark Veterinary: Direct-to-consumer dog genetic testing company using advanced sequencing for breed and health insights. While focused on DNA rather than microbiome, it is a comparable at-home canine diagnostic offering targeting similar pet-owner customers.
- PetDx: Veterinary diagnostics company developing liquid biopsy and molecular tests for cancer and disease detection in dogs. Comparable as a high-tech veterinary diagnostics platform targeting clinical decision-making.
- FidoCure: Genomics-driven precision medicine for dogs with cancer, partnering with veterinary oncologists. Relevant as a canine precision-health company using advanced molecular analysis for clinical applications.
Broad incumbents
- Wisdom Panel (Zoetis): Owned by Zoetis, the global animal health leader, Wisdom Panel offers dog DNA testing at scale. Comparable as a high-volume pet diagnostic service with veterinary and consumer channels.
- Basepaws (Zoetis): Cat and dog genetic testing platform now part of Zoetis' animal health portfolio. Relevant as a companion-animal genomics diagnostics company operating at the intersection of pet care and advanced laboratory science.
- IDEXX Laboratories: Global leader in veterinary diagnostics, including reference lab services and in-clinic analyzers. Broad incumbent whose vet-channel testing infrastructure could both compete with and partner alongside BIOME9's microbiome services.
- Antech Diagnostics (Mars Petcare): Veterinary reference laboratory network owned by Mars Petcare, offering an extensive menu of diagnostic tests to vet clinics in North America. Comparable as a scaled veterinary lab services platform inside a major pet care conglomerate.
Regional players
- Nom Nom (Mars Petcare): US-focused fresh pet food and pet health platform (now part of Mars Petcare) that has explored gut-health personalization. Comparable business model combining pet nutrition with health-data personalization, primarily serving a different geography.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
BIOME9 financial estimates
Financial estimateRevenue estimate
Valuation estimate
BIOME9 leadership team
Management profileNumber of profiles
Profiles8 records
BIOME9 funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BIOME9 M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BIOME9
What does BIOME9 do?
BIOME9 provides at-home canine gut microbiome testing via its GutDiscovery® kit, using Oxford Nanopore long-read 16S-rRNA V1–V9 sequencing analysed by the InvisibleHealth® AI platform to deliver species-level bacterial identification, pathogen detection, and personalised health reports. Test results drive tailored BiomeBites® daily supplement plans (pre, pro, and postbiotics). The professional GutDiscovery® service is sold exclusively to vets, behaviourists, and nutritionists, while a consumer-grade gut health test is distributed via Pooch & Mutt and research services are offered to academic and commercial organisations.
Is BIOME9 a public or private company?
BIOME9 is a private company. It is classified as corporate owned and is currently operating.
When was BIOME9 founded?
BIOME9 was founded in 2023. It employs 11 to 50 people.
Where is BIOME9 based?
BIOME9 is headquartered in London, United Kingdom, in the Europe region.
How does BIOME9 make money?
Three revenue lines are on record. GutDiscovery® Test Kits are the primary driver. The others are biomeBites® Personalised Supplements and research Services.
Who are BIOME9's main competitors?
Direct peers on record are AnimalBiome and Pooch & Mutt. Emerging players are Embark Veterinary, PetDx and FidoCure. Broad incumbents are Wisdom Panel (Zoetis), Basepaws (Zoetis), IDEXX Laboratories and Antech Diagnostics (Mars Petcare). Nom Nom (Mars Petcare) is listed as a regional player.
Does BIOME9 have an API?
No public API is recorded for BIOME9.
What industry is BIOME9 in?
BIOME9's product category is Veterinary Diagnostics. Its primary akta.pro industry code is HLAMADAC, Veterinary Microbiology & Infectious Disease Testing (Culture/PCR/Serology), with a secondary code of HLAGANAH, Microbiome & Metagenomics Services. Its NAICS code is 54194 and its SIC code is 8071.